Navigation Links
Osteotech Reports Third Quarter 2009 Financial Results

EATONTOWN, N.J., Nov. 5 /PRNewswire-FirstCall/ -- Osteotech, Inc. (Nasdaq: OSTE), a leader in the emerging field of biologic products for regenerative healing, today reported financial results for the third quarter ended September 30, 2009.

"During the third quarter of 2009, our focus was on the release of our three new biologic products MagniFuse(TM) Bone Graft, FacetLinx(TM) Fusion Technology and Plexur M® Innovative Grafting," said Sam Owusu-Akyaw, President and Chief Executive Officer of Osteotech. "All of these products have generated excitement among surgeons and our sales agencies. We have received very positive feedback from our surgeon customers and believe these products are well-positioned to become market leaders. Based upon the dynamic feedback we've received to date, we made additional and necessary enhancements to these product lines during the third quarter of 2009 incurring incremental costs and expenses of approximately $.4 million. We are focused on learning from the challenges associated with our previous product launches and working to ensure we can be responsive to the market's needs and flexible as new opportunities arise. We plan to continue to invest in these new products during the balance of 2009 because our future growth and profitability will be driven by our ability to be successful with the releases of these new and differentiated biologics. We feel confident we are taking the steps necessary to successfully position our new biologics in the procedure-specific markets they are designed to serve, although the required investments will impact our 2009 revenue and bottom line expectations."

"We have made notable progress in executing our product development and launch strategies throughout 2009, but we have also faced considerable challenges", continued Mr. Owusu-Akyaw. "Our domestic base business grew sequentially compared with the second quarter and year-over-year, which we believe provides tangible evidence that our growth strategy is gaining traction and that we are successfully executing. While we were able to achieve domestic sales growth, we have seen a slowdown in international sales, primarily due to our self-imposed temporary suspension of Bulgarian tissue in a key Asian market and the general economic and reimbursement conditions in Greece. Initially, we anticipated recovering some of the lost market share in the second half of 2009, but we now believe we have lost traction in these markets. For the three and nine months ended September 30, 2009, these markets generated revenue of $.3 million and $2.0 million, respectively, compared with $1.6 million and $5.4 million in the comparable periods of 2008."

Recent and Upcoming Corporate Developments

  • During the third quarter, Osteotech commercialized FacetLinx Fusion Technology for use in facet fusion procedures. Based upon surgeon feedback following the initial introduction, the Company made strategic changes to the instrumentation set to enhance the product's ease-of-use. Early in the fourth quarter, the Company commenced a limited launch of the product and early sales indicate that FacetLinx is quickly gaining traction among key surgeons.
  • Early in the fourth quarter, the Company announced the first U.S. spinal surgery using MagniFuse PC (Posterior Cervical), which marked the start of the controlled release for the Company's family of products based upon the MagniFuse technology platform. MagniFuse PC was utilized during a posterior cervical fusion surgery and was cited as being easy-to-use and intuitive with a differentiated self-contained delivery system unlike any other product on the market. Osteotech expects MagniFuse technology to be used in 25 procedures by the time of the North American Spine Society annual meeting in mid-November.
  • Osteotech intends to showcase its MagniFuse Technology and FacetLinx Fusion Technology at the North American Spine Society annual meeting in San Francisco, California from November 10 - 14, 2009.
  • During the third quarter, Osteotech began the process of analyzing data from the 60-patient DuraTech BioRegeneration Matrix clinical trial. Based upon the data analysis process, the Company now expects to file during the fourth quarter of 2009 a 510(k) application with the United States Food and Drug Administration (FDA) to secure marketing clearance for DuraTech. DuraTech is the first of several products under development based upon Osteotech's proprietary human collagen technology (HCT(TM)) platform.

Financial Results

Revenue for the three months ended September 30, 2009 was $23.0 million compared with $24.1 million for the three months ended September 30, 2008. The decline in revenue for the third quarter of 2009 compared with the same period of 2008 was primarily driven by the expected reduction in revenue from the services businesses. The services businesses include client services and private label demineralized bone matrix, which collectively declined $1.1 million to $.7 million in the third quarter of 2009 compared with the third quarter of 2008. Excluding client services and private label demineralized bone matrix revenue, third quarter 2009 revenues were essentially equivalent with third quarter 2008 revenues. International revenue was $4.6 million, a decline of $.5 million in the third quarter of 2009 compared with the same period of 2008 primarily reflecting the challenging general economic conditions and the lingering impact following the resolution of the Company's self imposed temporary suspension of tissue products processed from tissue recovered by its Bulgarian subsidiary. Domestic revenue in the Company's base business was approximately $17.7 million in the third quarter of 2009 and grew 3% compared with the same period of 2008, and 6% compared with the second quarter of 2009. The Company's base business excludes client services and private label demineralized bone matrix product revenues.

Revenue for the nine-month period ended September 30, 2009 was $70.4 million compared with $79.2 million reported for the same period of 2008. The decline in revenue for the nine-month period ended September 30, 2009 was primarily driven by: the expected reduction in revenue from the Company's services businesses, which declined $5.2 million, the aforementioned decline in international revenue and lower domestic unit sales volume.

Net loss for the third quarter ended September 30, 2009 was $1.9 million, or $0.11 per share, compared with net income of $58,000, or breakeven for the third quarter of 2008. Net loss for the nine-month period ended September 30, 2009 was $4.9 million, or $0.27 per share, compared with net income of $2.6 million, or $0.15 per diluted share, for the comparable period of 2008. The net loss in 2009 is primarily due to the Company's anticipated reductions in revenue and lower gross margins and, in the third quarter, higher-than-anticipated costs related to a variety of enhancements to its new procedure-specific biologic solutions.


Based upon the results achieved to date and the additional expenditures the Company expects to incur to support its enhanced launch strategies and product updates, Osteotech is updating the financial guidance it previously established for 2009:

  • Revenue is expected to range between $92 million and $94 million;
  • Net loss for 2009 is expected to be between $0.32 and $0.36 per share; and
  • The Company expects to exit 2009 with $9 million to $10 million in cash.

Conference Call Tomorrow, November 6, 2009

The Osteotech management team will host a conference call on November 6, 2009 at 9:00 a.m. (EST) to discuss third quarter 2009 financial results, recent corporate developments and guidance for 2009. The call can be accessed by dialing 1-866-770-7129 (domestic) or 1-617-213-8067 (international) and indicating access code 27776012. The conference will also be simultaneously webcast at A replay of the call will be available two hours after completion of the live call through midnight, Friday, November 20, 2009 by dialing 1-888-286-8010 and indicating access code 24133940.

About Osteotech

Osteotech, Inc., headquartered in Eatontown, New Jersey, is a global leader in providing biologic solutions for regenerative medicine to support surgeons and their patients in the repair of the musculoskeletal system through the development of innovative therapy-driven products that alleviate pain, promote biologic healing and restore function. For further information regarding Osteotech or the conference call, please go to Osteotech's website at

Certain statements made throughout this press release that are not historical facts are forward-looking statements (as defined in the Private Securities Litigation Reform Act of 1995) regarding the Company's future plans, objectives and expected performance. Any such forward-looking statements are based on assumptions that the Company believes are reasonable, but are subject to a wide range of risks and uncertainties and, therefore, there can be no assurance that actual results may not differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the Company's ability to develop and introduce new products, differences in anticipated and actual product and service introduction dates, the ultimate success of those products in the marketplace, the continued acceptance and growth of current products and services, the impact of competitive products and services, the availability of sufficient quantities of suitable donated tissue and the success of cost control and margin improvement efforts. Certain of these factors are detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission. All information in this press release is as of November 5, 2009 and the Company does not intend to update this information.

                              OSTEOTECH, INC. and Subsidiaries
                       (dollars in thousands, except per share data)

                               Three Months         Nine Months
                                   Ended               Ended
                               September 30,        September 30,
                             2009       2008       2009       2008

    Revenue               $22,961    $24,063    $70,363    $79,247
    Cost of Revenue        12,502     11,182     36,406     37,622
    Gross profit           10,459     12,881     33,957     41,625

    Marketing, selling and
      general and
      expenses             10,648     10,476     33,034     33,479
    Research and
      expenses              1,544      1,739      5,195      5,273
                           12,192     12,215     38,229     38,752

    Operating income
     (loss)                (1,733)       666     (4,272)     2,873

    Interest expense,
      net                    (354)     (276)     (1,063)      (762)
    Other                      58      (270)        106        953

    Income before
      income taxes         (2,029)       120     (5,229)     3,064
    Income tax
      provision (benefit)    (122)        62       (322)       452
    Net Income            $(1,907)   $    58    $(4,907)   $ 2,612
    Earnings per share:
         Basic            $ (0.11)   $     -    $ (0.27)    $ 0.15
         Diluted          $ (0.11)   $     -    $ (0.27)    $ 0.15
    Shares used in
      earnings (loss)
      per share:
         Basic         18,120,350 17,881,018 17,925,718 17,749,402
         Diluted       18,120,350 17,993,900 17,925,718 17,854,319

                                   (dollars in thousands)

                              Three Months         Nine Months
                                  Ended               Ended
                               September 30,       September 30,
                             2009      2008      2009      2008
    DBM                   $14,611   $14,023   $43,445   $47,564
    Hybrid/Synthetic          894       816     2,289     2,187
    Traditional Tissue      5,101     5,246    15,821    15,606
    Spinal Allografts       1,966     1,943     5,708     6,479
    Client Services           125     1,706     2,013     6,527
    Other Product Lines       264       329     1,087       884
    Revenue               $22,961   $24,063   $70,363   $79,247

                             OSTEOTECH, INC. and Subsidiaries
                                  (dollars in thousands)

                                            September 30,      December 31,
                                                 2009              2008

    Cash and cash equivalents                   $10,607           $18,823
    Accounts receivable, net                     19,393            17,968
    Deferred processing costs                    45,476            38,715
    Inventories                                   1,683             1,467
    Prepaid expenses and other current assets     2,303             3,115
                 Total current assets            79,462            80,088
    Property, plant and equipment, net           30,894            34,005
    Other assets                                  8,718            13,022
                                               $119,074          $127,115

        Liabilities and Stockholders' Equity

    Accounts payable and accrued liabilities    $19,973           $23,569
    Current maturities of capital lease
     obligation                                     968               895
                 Total current liabilities       20,941            24,464
    Capital lease obligation                     12,439            13,175
    Other liabilities                             6,742             6,626
                 Total liabilities               40,122            44,265
    Stockholders' equity                         78,952            82,850
                                               $119,074          $127,115

SOURCE Osteotech, Inc.

SOURCE Osteotech, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Osteotechs MagniFuse(TM) Technology Used in First U.S. Surgery
2. Osteotech Completes Enrollment for DuraTech(TM) BioRegeneration Matrix Clinical Trial
3. Osteotech Initiates Pivotal Clinical Trial for DuraTech(TM) BioRegeneration Matrix
4. Air Methods Reports 3Q2009 Results and 4Q2009 Update
5. Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009
6. InterMune Reports Third Quarter 2009 Financial Results and Business Highlights
7. Trubion Pharmaceuticals, Inc. Reports Third Quarter and Nine Months 2009 Financial Results
8. Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert
9. PDI Reports 2009 Third Quarter Financial Results
10. CareFusion Reports First Quarter Results, Raises Full-Year Outlook
11. Symmetry Medical Reports Third Quarter 2009 Financial Results
Post Your Comments:
(Date:10/11/2017)... Oct. 11, 2017  Caris Life Sciences ® , ... the promise of precision medicine, today announced that St. ... Precision Oncology Alliance™ (POA) as its 17 th ... St. Jude Crosson Cancer Institute will help develop standards ... of tumor profiling, making cancer treatment more precise and ...
(Date:10/7/2017)...   Provista, a proven leader in the ... purchasing power, today announced a new resource area on ... is the online home for case studies, articles ... news releases, slideshows and events. ... resources at their fingertips, viewers can also watch short ...
(Date:10/2/2017)... Oct. 2, 2017 Diplomat Pharmacy, Inc. (NYSE: ... Software and Consulting, LLC , and named its founder ... based in Tennessee , will operate ... expands EnvoyHealth,s service offerings for health care partners to ... "In an interoperable world, technology ...
Breaking Medicine Technology:
(Date:10/12/2017)... CITY, Fla. (PRWEB) , ... October 12, 2017 , ... ... cold therapy products, announced today the introduction of an innovative new design of the ... multipurpose pad so you get maximum comfort while controlling your pain while using cold ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the ... to develop to enable prevention of a major side effect of chemotherapy in ... in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at ... for the 49th Congress of the International Society of Paediatric Oncology (SIOP) ... Center for Cancer and Blood Disorders at Children’s National, and Stephen P. ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... nation's first interactive health literacy software tool, and the Cancer Patient Education Network ... cancer patient education, today announce a new strategic alliance. , As CPEN’s ...
(Date:10/12/2017)... ... 2017 , ... Farm Forward joins Bon Appétit ... institutions in announcing the launch of the Leadership Circle , a program ... raised for food. , Founding members of the Leadership Circle also include Airbnb’s ...
Breaking Medicine News(10 mins):